Jeffrey Bluestone, Sonoma CEO (Photo credit: Steve Babuljak)

Jeff Blue­stone just raised $265M to de­vel­op cu­ra­tive cell ther­a­pies. We asked him how

Jeff Blue­stone had some big goals in mind when he de­cid­ed to make a switch from a decades-long ca­reer in acad­e­mia and non-prof­it re­search to a biotech start­up CEO. And now — 18 months af­ter the $40 mil­lion launch par­ty — he has a whole lot more mon­ey on hand to pay for the con­sid­er­able amount of work ahead at Sono­ma Bio­ther­a­peu­tics.

This morn­ing Blue­stone is tak­ing the wraps off a $265 mil­lion B round af­ter boost­ing the core syn­di­cate of A-list in­vestors he start­ed with. Even by to­day’s stan­dards, that sum dwarfs the kind of $100 mil­lion-plus megarounds that have be­come stan­dard fare in biotech over the last 2 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.